Faruqi and Faruqui, LLP Logo
Share this page

Accelerate Diagnostics, Inc. (AXDX)

(NasdaqCM: AXDX)

Summary

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Accelerate Diagnostics, Inc. (AXDX) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NasdaqCM: AXDX).

The investigation focuses on whether the Company and its executives violated federal securities laws making materially false and misleading statements regarding the Company’s business, operations, and prospects.

On February 18, 2015, an article published on the website www.SeekingAlpha.com revealed that Accelerate had falsely represented that its technology BACcel involves a technique for diagnosing pathogens in a blood sample without a need for using a blood culture.  In reality, BACcel does require a blood culture which significantly reduces the value of the technology. 

Following this news, Accelerate stock declined by $4.04 per share, or more than 18%, closing on February 20, 2015 at $18.05 per share.

Take Action

If you invested in Accelerate stock or options through February 18, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Accelerate’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 03/13/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.